Esperion (ESPR) Q4 2025 earnings review
Top-Line Surge and IP Victories Set Stage for 'Vision 2040'
Esperion pre-announced a massive top-line beat for FY25, with Total Revenue hitting $400-$408M (+21.5% YoY) and U.S. Net Product Sales reaching $156-$160M (+36.5% YoY). Q4 retail prescription equivalents accelerated, growing 34% YoY and 11.3% sequentially. The quarter was headlined by a $90M milestone from Japanese partner Otsuka and sweeping legal settlements that protect the U.S. franchise from generic competition until 2040. Note: As this is a preliminary release, critical bottom-line metrics (Gross Margin, Net Income, EPS) were excluded, leaving profitability visibility clouded until the full March report.
🐂 Bull Case
Settlements with four ANDA filers, including Dr. Reddy’s, eliminate generic overhang until April 2040. This fundamentally changes the DCF valuation of the company and provides a 15-year runway to maximize the bempedoic acid franchise.
The $90M milestone from Otsuka (Japan) proves the international strategy is working. With Japan launching in late 2025/early 2026, and Daiichi Sankyo Europe treating over 600,000 patients, high-margin royalty streams are scaling rapidly.
🐻 Bear Case
The preliminary release touts top-line records but conveniently omits Net Income and Gross Margin. In Q3, gross margins compressed heavily to 52.7% due to low-margin partner tablet sales. Until full financials are released, earnings quality remains suspect.
The U.S. growth narrative relies heavily on NEXLETOL/NEXLIZET being included in the Q1 2026 U.S. Dyslipidemia Guidelines. Any delay or weak positioning in these guidelines could stall domestic momentum.
⚖️ Verdict: 🟢
Cautiously Bullish. The combination of strong Rx volume growth, a massive cash injection from the Otsuka milestone, and the 2040 IP extension heavily outweighs the lack of immediate bottom-line visibility. The core business is accelerating.
Key Themes
Commercial Execution Driving Prescription Acceleration
U.S. retail prescription equivalents grew 34% YoY and 11.3% sequentially in Q4. This Accelerating trend validates the company's aggressive pivot toward statin-intolerant patients (the 'Can’t take a statin?' campaign). The prescriber base expanded by 24% to nearly 45,000 healthcare providers in 2025, supported by >90% commercial and Medicare coverage.
Introducing 'Vision 2040' and Pipeline Expansion
Management formally pivoted from a single-asset commercial story to a broader pipeline narrative called 'Vision 2040'. The goal: 5+ marketed products. The key asset is ESP-2001, an ACLY inhibitor targeting Primary Sclerosing Cholangitis (PSC), which management sizes as a $1B+ market. IND-enabling studies are underway for a 2026 clinical start.
Margin Drag from Partner Manufacturing
While not detailed in the preliminary release, Q3 operating margins (-11.4%) and gross margins (52.7%) were dragged down by low-margin tablet sales to European partner Daiichi Sankyo. Management previously promised margin relief via a manufacturing tech transfer by early 2026. Without Q4 margin data, this remains a critical unresolved overhang.
Japan Approval Triggers Massive Capital Influx
Partner Otsuka secured regulatory and favorable National Health Insurance pricing approval in Japan, triggering a $90M total payment to Esperion. Japan is the third-largest global cardiovascular market. Combined with a $75M capital raise, this bolsters the balance sheet to ~$168M, effectively removing near-term dilution risks.
Triple-Combination Pill Targets 2027
Esperion is developing two oral triple-combination lipid-lowering tablets aimed for 2027 commercialization. Literature suggests these can lower LDL-C by >60%, positioning Esperion to compete directly on efficacy with injectable therapies (PCSK9s) but with the convenience of an oral dose.
Other KPIs
Accelerating. Up 20% to 23% compared to FY24. Excluding one-time milestones (like the $90M from Otsuka and prior year DSE milestones), underlying revenue grew a massive ~55% to 59%, proving the core commercial engine is finally humming.
Reversing the cash burn narrative. Up significantly from $92.4M at the end of Q3. This was driven by the $90M Otsuka milestone and a $75M capital raise. The company is now sufficiently capitalized to fund its 'Vision 2040' pipeline ambitions without immediate liquidity concerns.
Guidance
Stable. The midpoint of $227.5M is flat compared to the FY25 guidance range of $215-$235M. This demonstrates strong cost discipline. Management is funding the U.S. commercial expansion and the new ESP-2001 pipeline trials without inflating the overall expense base.
Accelerating. Implies 35% to 38% YoY growth. With Q1-Q3 actuals totaling $115.9M, this implies Q4 U.S. sales landed around $40.1M-$44.1M, representing steady sequential holding power despite historical Q4 seasonal market sluggishness.
Key Questions
Gross Margin Visibility
With the tech transfer to Daiichi Sankyo expected to complete around year-end, what is the expected gross margin run-rate for Q1 2026? Has the drag from low-margin partner tablet sales officially ended?
Profitability Target Status
In Q2 and Q3, management confidently guided to 'sustainable profitability beginning in Q1 2026'. Given the flat FY26 OpEx guidance and surging Rx volume, is this target still fully on track?
U.S. Guidelines ROI
You expect inclusion in the Q1 2026 U.S. Dyslipidemia Guidelines. How quickly do you expect this to translate into prescription acceleration, and are additional SG&A investments required to effectively market this new guideline status?